Greater China was Usana Health Sciences’s largest region in fiscal 2026, bringing in $424.54M of $920.91M (46%).
| Geography | FY 2011 | FY 2011 | FY 2012 | FY 2013 | FY 2015 | FY 2016 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2022 | FY 2023 | FY 2024 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Greater China | $475.10M | $457.98M | $424.54M | |||||||||||||
| Americas & Europe | — | — | — | |||||||||||||
| Southeast Asia/Pacific | — | — | — | |||||||||||||
| Southeast Asia Pacific | $163.89M | $146.80M | $132.00M | |||||||||||||
| United States | $95.91M | $91.80M | $224.89M | |||||||||||||
| China | — | — | — | |||||||||||||
| Hong Kong | — | — | — | |||||||||||||
| Korea, Republic Of | $99.11M | $76.45M | $68.86M | |||||||||||||
| South Korea | — | — | — | |||||||||||||
| North Asia | $101.45M | $78.21M | $70.63M | |||||||||||||
| Canada | — | — | — | |||||||||||||
| Total | $935.45M | $851.23M | $920.91M |
Usana Health Sciences brought in $920.91M from its five regions in fiscal 2026, the year ended January 3, 2026. That was up 8.2% from $851.23M in fiscal 2024, the previous year with figures. Greater China was the largest at $424.54M (46.1%), ahead of United States at $224.89M (24.4%) and Southeast Asia Pacific at $132.00M (14.3%). The other two regions brought in $139.48M combined.
Compared with fiscal 2024, the previous year with figures, United States grew fastest, up 145.0% to $224.89M, while Southeast Asia Pacific fell the most, down 10.1% to $132.00M. From fiscal 2023 to 2026, combined revenue from these regions fell from $935.45M to $920.91M, a compound annual decline of 0.5%. Greater China's share of the total fell from 50.8% to 46.1%.
Core Nutritional was Usana Health Sciences’s largest segment in fiscal 2026, bringing in $775.45M of $925.26M (84%).
| Segment | FY 2021 | FY 2022 | FY 2022 | FY 2023 | FY 2024 | FY 2026 |
|---|---|---|---|---|---|---|
| Direct Selling | — | — | — | |||
| Direct-Selling | — | — | — | |||
| Core Nutritional | $915.21M | $845.79M | $775.45M | |||
| Hiya Direct-To-Consumer | — | $1.97M | $131.97M | |||
| Other | $5.80M | $6.74M | $17.83M | |||
| All Other | — | — | — | |||
| Total | $921.01M | $854.50M | $925.26M |
Usana Health Sciences brought in $925.26M from its three segments in fiscal 2026, the year ended January 3, 2026. That was up 8.3% from $854.50M in fiscal 2024, the previous year with figures. Core Nutritional was the largest at $775.45M (83.8%), ahead of Hiya Direct-To-Consumer at $131.97M (14.3%) and Other at $17.83M (1.9%).
Compared with fiscal 2024, the previous year with figures, Hiya Direct-To-Consumer grew 6,599.0% to $131.97M, while Core Nutritional fell 8.3% to $775.45M.
Usana Health Sciences began breaking out Hiya Direct-To-Consumer in fiscal 2024, when it brought in $1.97M.
Usana Health Sciences (USNA) reports its revenue by geography and by segment. In fiscal 2026, Greater China was its largest region, bringing in $424.54M (46.1% of the total), followed by United States at $224.89M (24.4%).
Greater China was Usana Health Sciences' largest region in fiscal 2026, bringing in $424.54M, or 46.1% of the $920.91M total across its five regions.
Core Nutritional was Usana Health Sciences' largest segment in fiscal 2026, bringing in $775.45M, or 83.8% of the $925.26M total across its three segments.
Every figure comes from Usana Health Sciences' annual financial filings, as reported. Each line keeps the name Usana Health Sciences gives it, and years follow its fiscal calendar.
Usana Health Sciences' revenue by geography goes back to fiscal 2011, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.